Cargando…
A gene signature associated with PTEN activation defines good prognosis intermediate risk prostate cancer cases
Accurate identification of intermediate risk (Gleason 3 + 4 = 7) prostate cancer patients with low risk of disease progression is an unmet challenge in treatment decision making. Here we describe a gene signature that could guide clinicians in the selection of patients with intermediate stage clinic...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5903700/ https://www.ncbi.nlm.nih.gov/pubmed/29665325 http://dx.doi.org/10.1002/cjp2.94 |